EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of a mouse model humanized for cytochrome P450–mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs

Yury Kapelyukh, Charlotte Gabel-Jensen, Alastaire Kenneth MacLeod, Kevin-Sebastien Daniel Coquelin, Laste Stojanovski, Laura Frame, Amy Tavendale, Colin J Henderson, Kevin D Read, Charles Roland Wolf, Carolina Säll

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Yury Kapelyukh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Division, University of Dundee Medical School, Dundee, United Kingdom. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System, Cytochrome P-450 CYP1A2, Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk, University of Dundee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional preclinical in vitro approaches inaccurately predicted clinical trial outcomes of drug-drug interactions involving the peptide NN1177, a glucagon and glucagon-like peptide 1 receptor coagonist. To further study the mechanisms behind this discrepancy, we have exploited a mouse model (8HUM) humanized for the major cytochrome P450 (P450) enzymes involved in drug disposition in humans. We show that NN1177 administration to 8HUM mice suppressed hepatic in vivo expression of CYP3A4 (82% compared to vehicle) and CYP1A2 (58% compared to vehicle). This was consistent with in vitro sandwich culture hepatocyte data reported previously. However, reduction in CYP3A4 and CYP1A2 levels in vivo appeared to resolve over time, despite daily NN1177 administration. These findings suggest an adaptive response to the metabolic effects of NN1177. In vivo pharmacokinetic studies in 8HUM closely matched the findings observed in the clinical trial, because there was no relevant increase in the exposure of the CYP3A4 and CYP1A2 probe drugs. Furthermore, no suppression effects were observed when the mice had been pretreated with the inducing agents, St. John's wort or phenobarbital, respectively, suggesting that the mechanism of P450 reduction does not involve the transcription factors constitutive androgen receptor or pregnane X receptor. These data highlight the complexities associated with therapeutic peptide drug-drug interactions and the remaining challenges for accurate predictions of P450 suppression and potential clinical implications. The humanized 8HUM model provides a promising and informative preclinical tool that can add high value during drug development by providing further insights into the effects on P450 expression, together with the subsequent impact of coadministered probe drugs in an in vivo model. SIGNIFICANCE STATEMENT: The current work describes the application of a humanized cytochrome P450 mouse model that provides further insight into the potential mechanisms and outperforms conventional in vitro approaches for preclinical predictions of peptide drug-drug interaction risk. The results showed no significant effects on the Cooperstown 5 + 1 cocktail, in line with clinical findings, and thereby represent an exciting model to further explore future therapeutic peptide projects during drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemCytochrome P-450 CYP1A2PeptidesAnimalsDrug InteractionsMiceHumansMaleHepatocytesLiverMicrosomes, LiverModels, Animal

Stichwörter der Autor:innen

Cytochrome P450Drug-drug interaction predictionsDrug/drug interactionsGlucagon-like peptide 1Humanized modelsPeptide/small molecule drug-drug interaction

Substanzen

Cytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemCytochrome P-450 CYP1A2Peptides

Autor:innen und Institutionen

  • Cancer Research Division, University of Dundee Medical School, Dundee, United Kingdom.
  • Development ADME, Novo Nordisk A/S, Måløv, Denmark.
  • Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry, University of Dundee, Dundee, United Kingdom.
  • Cancer Research Division, University of Dundee Medical School, Dundee, United Kingdom; Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
  • Cancer Research Division, University of Dundee Medical School, Dundee, United Kingdom. Electronic address: c.r.wolf@dundee.ac.uk.

Förderung

  • Novo Nordisk
  • University of Dundee

Zitieren

APA

Kapelyukh, Y., Gabel-Jensen, C., MacLeod, A. K., Daniel Coquelin, K. S., Stojanovski, L., Frame, L., Tavendale, A., Henderson, C. J., Read, K. D., Wolf, C. R., & Säll, C. (2025). Application of a mouse model humanized for cytochrome P450–mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100153

Vancouver

Kapelyukh Y, Gabel-Jensen C, MacLeod AK, Daniel Coquelin KS, Stojanovski L, Frame L, et al. Application of a mouse model humanized for cytochrome P450–mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100153

BibTeX
@article{Kapelyukh2025,
  author = {Kapelyukh, Yury and Gabel-Jensen, Charlotte and MacLeod, Alastaire Kenneth and Daniel Coquelin, Kevin-Sebastien and Stojanovski, Laste and Frame, Laura and Tavendale, Amy and Henderson, Colin J and Read, Kevin D and Wolf, Charles Roland and Säll, Carolina},
  title = {Application of a mouse model humanized for cytochrome P450–mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100153}
}
Kostenlos starten →